<body><script type="text/javascript"> function setAttributeOnload(object, attribute, val) { if(window.addEventListener) { window.addEventListener('load', function(){ object[attribute] = val; }, false); } else { window.attachEvent('onload', function(){ object[attribute] = val; }); } } </script> <div id="navbar-iframe-container"></div> <script type="text/javascript" src="https://apis.google.com/js/platform.js"></script> <script type="text/javascript"> gapi.load("gapi.iframes:gapi.iframes.style.bubble", function() { if (gapi.iframes && gapi.iframes.getContext) { gapi.iframes.getContext().openChild({ url: 'https://www.blogger.com/navbar/5621345630369022014?origin\x3dhttp://cderwn.blogspot.com', where: document.getElementById("navbar-iframe-container"), id: "navbar-iframe" }); } }); </script>

Drug Evaluation & Research

CDERNEW-TEXT 10/31/2007


Thursday, November 1, 2007

October 31, 2007

Drugs@FDA Downloadable Data Files
http://www.fda.gov/cder/drugsatfda/datafiles/default.htm

(updated)

FDA approves Tasigna (nilotinib) for the treatment of Philadelphia
chromosome positive chronic myeloid leukemia
http://www.fda.gov/bbs/topics/NEWS/2007/NEW01734.html .

New and Generic Drug Approvals
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm

Baclofen 10mg Tablets, Impax Labs, Approval

Baclofen 20mg Tablets, Impax Labs, Approval

Cetirizine Hydrochloride Syrup, Taro Pharma, Tentative Approval

Cetirizine Hydrochloride Tablets, Cipla Ltd., Tentative Approval

Fenofibrate Tablets, Par Pharma, Control Suppl.

Levocarnitine Oral Solution, P3 Labs, Approval

Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol,
Astra Zeneca, Control Supp.

Requesting a Pre-Assigned Electronic Common Technical Document (eCTD)
Number from Office of Generic Drugs
http://www.fda.gov/cder/ogd/request_preassigned_ectd.htm


------------------------------------------------
To subscribe or to unsubscribe from CDERNEW-TEXT

http://list.nih.gov/archives/cdernew-text.html
------------------------------------------------

posted by Mags @ 11:23 AM,




0 Comments:

Post a Comment

<< Home